| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lapatinib is a tyrosine kinase inhibitor primarily used in the treatment of HER2-positive breast cancer, among other cancer types. Its mechanism of action involves binding to the intracellular ATP-binding sites of the HER1 (also known as EGFR) and HER2 receptors, thereby inhibiting their autophosphorylation and subsequent activation of downstream signaling pathways. The major pathways involved include: -PI3K/AKT/mTOR Pathway Inhibition of this pathway leads to reduced cell survival and proliferation, as it normally promotes growth and survival signals through downstream effectors. -RAS/RAF/MEK/ERK (MAPK) Pathway Blocking the activation of this cascade affects cell cycle progression, proliferation, and differentiation. In many cancers, dysregulation of this pathway contributes to uncontrolled growth. By interfering with these signaling cascades, lapatinib can reduce tumor cell proliferation, induce apoptosis (programmed cell death), and potentially increase the sensitivity of tumor cells to additional therapeutic agents. The induction of oxidative stress is one of the ways by which lapatinib can exert cytotoxic effects on cancer cells. Elevated ROS levels can damage cellular components, such as lipids, proteins, and DNA, thereby contributing to cell death. Lapatinib — an orally administered small-molecule 4-anilinoquinazoline tyrosine kinase inhibitor that reversibly inhibits the intracellular kinase domains of HER2/ErbB2 and EGFR/ErbB1. It is a dual HER2/EGFR targeted anticancer drug, commonly abbreviated LAP or lapatinib, and is marketed as Tykerb. It is used primarily in HER2-positive advanced or metastatic breast cancer in combination with capecitabine or, in hormone-receptor-positive disease, letrozole. It remains marketed in Canada and has an active U.S. prescription-drug label. Its contemporary clinical role is generally later-line or context-dependent because newer HER2-directed agents provide superior efficacy in many treatment sequences. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral absorption is incomplete and highly variable. At 1,250 mg/day, steady-state Cmax is approximately 2.43 µg/mL and AUC approximately 36.2 µg·h/mL; effective half-life is approximately 24 hours. Lapatinib is more than 99% protein bound and is extensively metabolized mainly by CYP3A4/3A5. Food markedly increases exposure, with approximately 3- to 4-fold increases in AUC depending on meal composition; consequently the approved regimen specifies administration at least one hour before or one hour after food. Strong CYP3A4 inhibitors and inducers can substantially alter exposure. Normal-brain penetration is poor because lapatinib is a P-gp/BCRP substrate, although penetration can be greater in disrupted brain metastases. In-vitro vs systemic exposure relevance: Clinically observed total plasma Cmax at 1,250 mg/day corresponds roughly to low-micromolar total lapatinib concentrations, but more than 99% protein binding means free systemic concentrations are substantially lower. Experiments using approximately 0.1–1 µM may therefore be reasonably relevant to tumor exposure depending on tissue accumulation and protein conditions, whereas mechanistic studies using 5–20 µM, particularly NRF2/hepatotoxicity studies, substantially exceed typical unbound systemic exposure and should be interpreted primarily as mechanistic or toxicity models rather than direct therapeutic-equivalent exposure. Clinical evidence status: Approved targeted therapy / Phase III RCT evidence / combination treatment. Lapatinib has demonstrated clinical benefit with capecitabine in previously treated HER2-positive advanced breast cancer and with letrozole in HR-positive/HER2-positive metastatic breast cancer. It remains marketed, including in Canada, but has largely moved to later-line or alternative use because trastuzumab deruxtecan, tucatinib-containing regimens and other newer HER2-directed therapies generally occupy preferred contemporary treatment positions. Major safety constraints include boxed-warning hepatotoxicity, diarrhea, reduced left-ventricular ejection fraction, QT prolongation, interstitial lung disease/pneumonitis, severe cutaneous reactions and clinically important CYP3A4-mediated drug interactions. Lapatinib Mechanistic Profile
|
| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 8171- | Lap, | Effects of food on the relative bioavailability of lapatinib in cancer patients |
| - | Trial, | Var, | NA |
| 8172- | Lap, | Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study |
| - | Trial, | BC, | NA |
| 8174- | Lap, | Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:109 Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid